A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Nilutamide (Nilandron)

Androgen Receptor Inhibitor class · 1 generic manufacturer · 1 ANDAs filed at FDA.

First FDA approval2013-07-15
Generic availableYes · 1 mfrs
Shortage statusDiscontinued
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$1.4M in CY2024 Part D spend406 claims · 78 beneficiaries · 329 plans surveyed

Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
37 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Nilutamide used for?

Nilutamide is a Androgen Receptor Inhibitor medication tracked in Medicare Part D.

Is there a generic for Nilutamide?

Yes. 1 ANDAs filed at FDA, 1 generic manufacturers currently shipping.

How much does my plan pay for Nilutamide?

NADAC pricing data not currently available for this drug.

Is Nilutamide on the FDA shortage list?

Nilutamide has been discontinued by its manufacturer(s).

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Androgen Receptor Inhibitor4 alternatives in D1
01
Bicalutamide
Brand: CASODEX
$0.403Lowest NADAC
6Generic mfrs
$10.9MCY24 Part D spend
Compare →
02
Clascoterone
Brand: Winlevi
$9.99Lowest NADAC
0Generic mfrs
$1.7MCY24 Part D spend
Compare →
03
Enzalutamide
Brand: Xtandi
Lowest NADAC
0Generic mfrs
$5.84BCY24 Part D spend
Compare →
04
Flutamide
Brand: Eulexin
Lowest NADAC
1Generic mfrs
$216,500CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (2 approvals on file) · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.